Plain-English translation of NCT04481256 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new immunotherapy drug called given alongside two chemotherapy drugs ( and ) and radiation therapy for people with squamous cell carcinoma of the esophagus. The goal is to see whether this medication helps the body's immune system fight the cancer more effectively while working together with traditional chemotherapy and radiation. This is a small feasibility study designed to understand if this combination is safe and practical for patients.
Currently, people with this type of esophageal cancer are treated with chemotherapy and radiation, but outcomes could be better. Researchers believe that adding this new immunotherapy medication might help by boosting the immune system's ability to recognize and destroy cancer cells, potentially improving survival and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy infusions intravenously on six different days over about six weeks, along with the new immunotherapy medication given intravenously three times during that period. At the same time, you would undergo radiation therapy five days a week for nearly six weeks. The entire treatment course lasts approximately six weeks, and you would need to attend the treatment center regularly for these sessions and follow-up appointments to monitor your response and any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Netherlands
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
UMC Utrecht, Catharina Ziekenhuis Eindhoven
Enrollment target
~49 participants
Started
November 2020
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Linde M Veen, MD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.